<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Memory Lane - Treatment Breakthroughs</title>
  <link rel="stylesheet" href="../css/style.css">
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.0.0-beta3/css/all.min.css">
  <style>
    :root {
      --primary: #4a6fa5;
      --secondary: #166088;
      --accent: #ff7e5f;
      --light: #f8f9fa;
      --dark: #343a40;
      --gray: #6c757d;
    }

    body {
      background-color: #f5f7fa;
      font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
      margin: 0;
      color: #333;
      line-height: 1.8;
    }

    header {
      background: linear-gradient(135deg, var(--primary), var(--secondary));
      color: white;
      padding: 1rem 0;
      box-shadow: 0 2px 10px rgba(0,0,0,0.1);
    }

    .container {
      width: 85%;
      max-width: 1200px;
      margin: 0 auto;
    }

    .header-content {
      display: flex;
      justify-content: space-between;
      align-items: center;
    }

    .logo {
      font-size: 1.8rem;
      font-weight: 700;
      display: flex;
      align-items: center;
      text-decoration: none;
      color: white;
    }

    .logo i {
      margin-right: 10px;
      color: var(--accent);
    }

    nav ul {
      display: flex;
      list-style: none;
      margin: 0;
      padding: 0;
    }

    nav ul li {
      margin-left: 1.5rem;
    }

    nav ul li a {
      color: white;
      text-decoration: none;
      font-weight: 500;
      transition: color 0.3s ease;
    }

    nav ul li a:hover {
      color: var(--accent);
    }

    main {
      padding: 2rem 0;
    }

    .page-title {
      text-align: center;
      color: var(--secondary);
      margin-bottom: 2rem;
      padding-bottom: 1rem;
      border-bottom: 2px solid var(--light);
    }

    .content {
      max-width: 800px;
      margin: 0 auto;
      font-size: 1.1rem;
    }
    
    .content p {
      margin-bottom: 1.5rem;
    }
    
    .content h2 {
      color: var(--secondary);
      margin: 2rem 0 1rem;
      padding-bottom: 0.5rem;
      border-bottom: 1px solid #eee;
    }
    
    .highlight-box {
      background-color: rgba(255, 126, 95, 0.1);
      border-left: 4px solid var(--accent);
      padding: 1.5rem;
      margin: 2rem 0;
      border-radius: 0 4px 4px 0;
    }
    
    .drug-list {
      list-style-type: none;
      padding-left: 0;
    }
    
    .drug-list li {
      margin-bottom: 1.5rem;
      padding-left: 2rem;
      position: relative;
    }
    
    .drug-list li::before {
      content: "•";
      position: absolute;
      left: 0;
      color: var(--accent);
      font-size: 1.5rem;
      line-height: 1;
    }
    
    .references {
      margin-top: 4rem;
      padding-top: 2rem;
      border-top: 1px solid var(--gray);
    }

    .references h2 {
      color: var(--secondary);
      margin-bottom: 1.5rem;
    }

    .reference-list {
      list-style-type: none;
      padding-left: 0;
    }

    .reference-list li {
      margin-bottom: 1.5rem;
      text-indent: -36px;
      padding-left: 36px;
      line-height: 1.5;
      font-size: 0.95rem;
    }

    .reference-list a {
      color: var(--primary);
      word-break: break-all;
      text-decoration: none;
    }

    .reference-list a:hover {
      text-decoration: underline;
    }
    
    @media (max-width: 768px) {
      .header-content {
        flex-direction: column;
        text-align: center;
      }
      
      nav ul {
        margin-top: 1rem;
        justify-content: center;
      }
      
      nav ul li {
        margin: 0 0.75rem;
      }

      .reference-list li {
        text-indent: -28px;
        padding-left: 28px;
        font-size: 0.85rem;
      }
    }
  </style>
</head>
<body>
  <header>
    <div class="container header-content">
      <a href="../index.html" class="logo">
        <i class="fas fa-brain"></i>
        <span>Memory Lane</span>
      </a>
      <nav>
        <ul>
          <li><a href="../index.html#stories">Stories</a></li>
          <li><a href="../index.html#tips">Tips</a></li>
          <li><a href="../index.html#research">Research</a></li>
          <li><a href="../index.html#resources">Resources</a></li>
        </ul>
      </nav>
    </div>
  </header>

  <main>
    <div class="container">
      <h1 class="page-title">Alzheimer's Treatment Breakthroughs</h1>
      <div class="content">
        <p>Recent clinical trials have marked a turning point in Alzheimer's disease treatment, with several new drugs demonstrating the ability to slow cognitive decline. These developments reflect a growing arsenal of tools that could fundamentally reshape Alzheimer's care.</p>

        <h2>Anti-Amyloid Therapies</h2>
        
        <ul class="drug-list">
          <li>
            <strong>Donanemab (Kisunla):</strong> Shows 30-35% reduction in disease progression during early stages, reducing amyloid plaques by 84% over 18 months. Offers patients up to 10 months of extended independent living.
          </li>
          <li>
            <strong>Lecanemab (Leqembi):</strong> Similar efficacy to donanemab, with European regulators approving it after initial doubts about its benefits.
          </li>
        </ul>

        <div class="highlight-box">
          <p>Both donanemab and lecanemab have received regulatory approvals in both the U.S. and Europe, signaling growing global access to these treatments.</p>
        </div>

        <h2>Repurposed Medications</h2>
        
        <ul class="drug-list">
          <li>
            <strong>Nucleoside reverse transcriptase inhibitors (NRTIs):</strong> These HIV drugs are now linked to a reduced risk of Alzheimer's, potentially preventing up to 1 million new cases annually.
          </li>
          <li>
            <strong>GLP-1 receptor agonists:</strong> Diabetes medications like semaglutide and liraglutide are under investigation for their neuroprotective benefits.
          </li>
        </ul>

        <h2>Emerging Therapies</h2>
        
        <ul class="drug-list">
          <li>
            <strong>ALZ-801:</strong> An oral drug specifically targeting APOE4 carriers has entered Phase 3 trials with promising results.
          </li>
          <li>
            <strong>Gene and cell therapies:</strong> Experimental treatments like Lomecel-B and SNK01 are showing early potential in reducing cognitive decline.
          </li>
          <li>
            <strong>Non-invasive approaches:</strong> Techniques like transcranial magnetic stimulation are demonstrating benefits in early trials.
          </li>
        </ul>

        <section class="references">
          <h2>References</h2>
          <ol class="reference-list">
            <li>Scripps News. (2024, January 31). FDA approves Alzheimer's drug that may slow memory decline in those with disease <a href="https://www.scrippsnews.com/politics/health-care/fda-approves-alzheimers-drug-shown-to-slow-decline-in-memory-cognition-in-those-with-the-disease">https://www.scrippsnews.com/politics/health-care/fda-approves-alzheimers-drug-shown-to-slow-decline-in-memory-cognition-in-those-with-the-disease</a></li>
            <li>MedPath. (2025, February 13). New analysis shows next-gen Alzheimer's drugs add 8–10 months of independent living <a href="https://trial.medpath.com/news/8fa0e753d710fdcc/new-analysis-shows-next-gen-alzheimer-s-drugs-add-8-10-months-of-independent-living">https://trial.medpath.com/news/8fa0e753d710fdcc/new-analysis-shows-next-gen-alzheimer-s-drugs-add-8-10-months-of-independent-living</a></li>
            <li>AP News. (2025, April 15). European regulators OK Alzheimer's treatment Leqembi after initial doubts. <a href="https://apnews.com/article/ea22a1f7d4d4e69dfc2a2c94412a6f35">https://apnews.com/article/ea22a1f7d4d4e69dfc2a2c94412a6f35</a></li>
            <li>New York Post. (2025, May 12). Doctors discover drug already on the market could prevent 1M new cases of Alzheimer's a year. Retrieved from <a href="https://nypost.com/2025/05/12/health/drug-could-prevent-1m-new-alzheimers-cases-a-year-study/">https://nypost.com/2025/05/12/health/drug-could-prevent-1m-new-alzheimers-cases-a-year-study/</a></li>
            <li>Alzheimer's Association. (2024). Alzheimer's research advances at AAIC 2024. <a href="https://aaic.alz.org/releases-2024/highlights-aaic-2024.asp">https://aaic.alz.org/releases-2024/highlights-aaic-2024.asp</a></li>
            <li>MedPath. (2025, February 5). Alzheon to present Phase 3 data for novel ApoE4-targeted Alzheimer's pill in April 2025 <a href="https://trial.medpath.com/news/9da97981201d78c5/alzheon-to-present-phase-3-data-for-novel-apoe4-targeted-alzheimer-s-pill-in-april-2025">https://trial.medpath.com/news/9da97981201d78c5/alzheon-to-present-phase-3-data-for-novel-apoe4-targeted-alzheimer-s-pill-in-april-2025</a></li>
            <li>MedPath. (2024, November 30). Alzheimer's disease: Cell and gene therapy advances in 2024 <a href="https://trial.medpath.com/news/6e186ced3c6f79d9/alzheimer-disease-awareness-month-2024-looking-back-at-a-year-of-progress-in-cell-and">https://trial.medpath.com/news/6e186ced3c6f79d9/alzheimer-disease-awareness-month-2024-looking-back-at-a-year-of-progress-in-cell-and</a></li>
            <li>BrightFocus Foundation. (2024, October 15). Breaking news dispatch: A non-invasive Alzheimer's treatment, early detection, and more. <a href="https://www.brightfocus.org/news/breaking-news-dispatch-a-non-invasive-alzheimers-treatment-early-detection-and-more">https://www.brightfocus.org/news/breaking-news-dispatch-a-non-invasive-alzheimers-treatment-early-detection-and-more</a></li>
          </ol>
        </section>
      </div>
    </div>
  </main>
</body>
</html>
